| Title: |
Sanofi bounces midstage ILT2 asset back to Biond Biologics after $125M bet. |
| Authors: |
Becker, Zoey (AUTHOR) |
| Source: |
FierceBiotech. 3/3/2025, pN.PAG-N.PAG. 1p. |
| Subject Terms: |
Monoclonal antibodies, Biologicals, Tumors |
| Abstract: |
Sanofi is handing back the tumor candidate after initiating a phase 2 trial of the anti-ITL2 monoclonal antibody. [ABSTRACT FROM AUTHOR] |
|
Copyright of FierceBiotech is the property of Questex Media Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Business Source Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
